21May 2024
Study Reveals Treatment Patterns and Outcomes in Metastatic Bladder Cancer

Study Reveals Treatment Patterns and Outcomes in Metastatic Bladder Cancer

A real-world data study examined the first-line systemic therapies for metastatic urothelial carcinoma of the bladder (mUC). Analyzing 4,169 patients, it found that older age and higher comorbidity burden were associated with receiving immunotherapy over chemotherapy. Treatment at academic facilities correlated with a higher likelihood of combination chemoimmunotherapy. Importantly, combination therapy demonstrated improved survival compared to chemotherapy alone. These findings suggest a nuanced approach to treatment selection based on patient demographics and treatment setting. Additionally, the study highlights the potential benefits of combination chemoimmunotherapy, particularly in academic centres, for metastatic bladder cancer.

  • #urology

Like

Save

Share